Thornton Michael Milos's Form 4 filing
ENDRA Life Sciences Inc. (NDRA) · filed May 23, 2022
- Accession no.
- 0001209191-22-031319
- Filed
- May 23, 2022, 4:30 PM ET
- Trade date
- May 18, 2022
- Filing delay
- 5 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $5.50K. It was filed 5 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thornton Michael MilosCIK 0001706297 | Officer (Chief Technology Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2022 | Common Stock | PPurchaseAcquired | +25,000 | $0.22 | +$5,500 | 307,775 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.